What's New
COVID-19 Important information
In response to the Government's recommendations on COVID-19 Medsafe staff are working from home.
Important Information for Medsafe CustomersSubmitting applications electronically to Medsafe
What to do in the case of a potential out of stock
Alert Level 4 - Manufacturers and suppliers of medicines as essential services
Medicine repurposing to treat COVID-19 infections
Pharmacy Licensing: Closure & Relocation
Visitors to New Zealand who need more of their regular prescribed medicine
COVID-19 - point of care test kits - restriction on importation, manufacture, supply and use
Potential shortage of fentanyl injection - use of unapproved product
News and Events
| Date | Type | Title |
|---|---|---|
| 4/06/2020 | Publications | Prescriber Update 41(2) - June 2020 |
| 28/05/2020 | Alert Communication | Miracle Mineral Solution - dangerous and potentially life-threatening side effects |
| 21/05/2020 | Monitoring Communication | Update - Possible risk of vasculitis with dabigatran (Pradaxa) |
| 21/05/2020 | Monitoring Communication |  Potential interaction between fluoxetine and
levothyroxine |
| 18/05/2020 | Media Release | Artemisia Annua extract becomes prescription only medicine |
| 1/05/2020 | Dear Healthcare Professional Letter | Use of Hydroxychloroquine [Plaquenil] in the context of COVID 19 - Risk of QT prolongation and drug/drug interactions (PDF, 4 pages, 358 KB) |
| 29/04/2020 | Committees | Minutes of the 181st Medicines Adverse Reactions Committee meeting |
| 22/04/2020 | Medicines | COVID-19 - point of care test kits - restriction on importation, manufacture, supply and use |
| 13/04/2020 | Medicines | Visitors to New Zealand who need more of their regular prescribed medicine |
